impax laboratories inc (IPXL) Key Developments
Impax Receives FDA Approval for Generic Version of Testred C-III
Sep 22 15
Impax Laboratories Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Testred Capsules 10 mg.
Impax Laboratories Inc. Receives FDA Approval for Generic Version of Mestinon Timespan Tablets, 180 mg
Sep 17 15
Impax Laboratories Inc. announced that the U.S. Food and Drug Administration (FDA) has approved generic Mestinon Timespan Tablets (pyridostigmine bromide extended release), 180 mg. The company is in the final stages of preparing for commercialization of this product through Impax's generic division. Mestinon Timespan Tablets is indicated for the treatment of myasthenia gravis.
Impax Laboratories Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 10:30 AM
Sep 11 15
Impax Laboratories Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-18-2015 10:30 AM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Bryan M. Reasons, Chief Financial Officer and Senior Vice President of Finance, George Frederick Wilkinson, Chief Executive Officer, President and Director.
Impax Laboratories Inc. - Special Call
Sep 8 15
To receive written notice from the United States Food and Drug Administration (FDA) verifying that the company has addressed all items raised by the FDA in the May 2011 Warning Letter relating to its Hayward, California manufacturing facility
Avanir Pharmaceuticals, Inc. Announces Appeals Court Ruling in NUEDEXTA Patent Case in US Against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc
Aug 27 15
Avanir Pharmaceuticals, Inc. has announced that a panel of the US Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA, a FDA-approved product for the treatment of Pseudobulbar affect, or PBA. The decision confirms patent protection for NUEDEXTA, or the 282 patent and the 484 patent, until 2026 in the US. The Appeals Court ruling affirmed the April 2014 decision upholding the '282' and '484' patents' validity by the US District Court for the District of Delaware in a lawsuit brought by Avanir against the Par Pharmaceuticals, Inc. and Impax Laboratories, Inc.